Advancing Cancer Diagnostics with Artificial Intelligence (AI) and Biomedical Vibrational Spectroscopy for Identifying Chemical Changes Associated with Breast Cancer

The CARTITUDE-1 study is a stage 1B / II clinical trial. The trial targeted B-cell maturation antigen by targeting CAR-T cell therapy in patients with multiple myeloma who had received at least three previous lines of treatment with standard drugs, including proteasome inhibitors, immunosuppressive drugs, and CD38 antibodies. Cilta-cel is made from the patient's own T cells, which is genetically engineered and is given as a single injection. The overall response rate to treatment was 97%, while the complete response rate and progression-free survival rate were 67% and 77%, respectively. The overall survival rate was 89%. Updates to this study were recently presented at the annual meeting of the American Clinical Oncology Association after our paper was accepted for publication in The Lancet. Our ASCO presentation showed a deeper response for patients receiving this treatment. These results are very impressive for patients with myeloma who have already undergone many treatment lines for their disease. It will be important to better understand the clinical features of patients who have experienced long-term recovery from this treatment and the mechanisms by which patients’ relapse. While it is not possible to formally conduct two separate single-arm studies on the idea of cells and cilia, the rate of dramatic response and progression-free survival of eyelash-treated patients is very interesting.Keywords: Cancer; Cells; Tissues; Tumors; Prevention; Prognosis; Diagnosis; Imaging; Screening; Treatment; Management